# US 2024/0197672 A1 · Composition for inhibiting skin pigmentation through autophagy activity containing procyanidin a2 and quercetin, as active ingredients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197672 A1
- Document ID: US20240197672A1
- Status: Published application
- Kind: A1
- Application number: 18/515,486
- Filed: 2023-11-21
- Published: 2024-06-20
- Earliest claimed: 2022-11-21
- Assignees: Kyungpook National University Industry-Academic Cooperation Foundation
- Applicants: Kyungpook National University Industry-Academic Cooperation Foundation
- Inventors: Sang-Han LEE; Borim SONG
- Web page: https://patentgrep.com/patent/US20240197672A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 8/49: containing heterocyclic compounds
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 8/602: {Glycosides, e.g. rutin}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 17/00: Drugs for dermatological disorders
- A61Q 19/02: for chemically bleaching or whitening the skin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to a composition for inhibiting skin pigmentation through enhanced autophagy activity, comprising procyanidin A2 and quercetin as active ingredients. The combination of procyanidin A2 and quercetin compounds not only inhibits tyrosinase but also increases autophagy activity, thus showing remarkable effectiveness in inhibiting melanin synthesis. Therefore, this composition can be advantageously used in various materials, including food products, cosmetic compositions, and pharmaceutical compositions, associated with skin pigmentation.

## Claims

### Claim 1

A method for skin whitening, or treating or alleviating skin pigmentation, comprising: administering a composition comprising procyanidin A2 and quercetin as active ingredients to a subject in need thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the procyanidin A2 and the quercetin are in a weight ratio of 1:2 to 2:1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises procyanidin A2 and quercetin each at a concentration of 20 μM.

### Claim 5 (depends on 1)

The method of claim 1, wherein the procyanidin A2 is in an amount greater than 0 and less than or equal to 50 μM.

### Claim 6 (depends on 1)

The method of claim 1, wherein the quercetin is in an amount greater than 0 and less than or equal to 25 μM.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition inhibits the activity of tyrosinase.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition inhibits the amount of melanin produced.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition decreases the expression of one or more melanin synthesis-related genes selected from the group consisting of tyrosinase, TRP-1, TRP-2, and MITF.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition increases the expression of at least one gene of (a), and decreases the expression of at least one gene of (b):
(a) LC3-II, ATG5, and Beclin-1; and
(b) p62, and LC3-I.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition inhibits an autophagy inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the autophagy inhibitor is one or more selected from the group consisting of wortmannin, bafilomycin, and 3-Methyladenine (3-MA).

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition is a health functional food composition, a functional food composition, a cosmetic composition, a quasi-drug composition, or a pharmaceutical composition.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cosmetic composition is at least one selected from the group consisting of a flexible cosmetic water, nutrition cosmetic water, gel, essence, spray essence, emulsion, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, cleanser and bath powder, mask pack, massage cream, hand cream, sunscreen, body lotion, and body cleanser.

### Claim 15

(canceled)

### Claim 16 (depends on 13)

The composition of claim 13, wherein the quasi-drug composition is for non-oral administration.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein the skin pigmentation disorder is one or more selected from the group consisting of melasma, freckles, lentigo, seborrheic keratosis, mole, café-au-lait spots, nevus of Ota, blue nevus, hyperpigmented spots, drug-induced hyperpigmentation, gravidic chloasma, and post-inflammatory hyperpigmentation due to wounds or dermatitis.
